Etoricoxib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Etoricoxib: From COX-2 Inhibitor Pain Relief to Migraine Disorder
One-Sentence Summary
Etoricoxib is a selective COX-2 inhibitor anti-inflammatory drug, registered in South Africa as Erestz. The TxGNN model predicts it may be effective for migraine disorder (score 99.90%), but 0 clinical trials and 0 publications currently support this specific prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the SAHPRA record supplied. Etoricoxib is generally used as an NSAID for pain and inflammation. |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L5 (model prediction only) |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack. Etoricoxib is a selective COX-2 inhibitor. COX-2-derived prostaglandins contribute to neurogenic inflammation and sensitisation of the trigeminovascular system, which is a recognised part of migraine biology. The mechanistic link is therefore plausible.
The original indication is not recorded in the local registration data, so the link cannot be checked against the approved use. The very high TxGNN score is a prediction only.
Some related predictions have small amounts of supporting literature:
- Headache disorder: case reports and a case series describe responses to etoricoxib in rare primary headaches (stabbing headache, cough headache, indomethacin-responsive headaches).
- Trigeminal autonomic cephalalgia: one case series (PMID 35277974) reports etoricoxib and celecoxib sensitivity.
These are non-controlled reports on other headache disorders. They do not establish efficacy in migraine.
Clinical Trial Evidence
Currently no related clinical trials registered for migraine disorder. No SANCTR or PACTR records were supplied.
Literature Evidence
Currently no related literature available for migraine disorder.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 49/20.2.8/0399 | Erestz | Film-coated tablet (Fct) | Not stated in the supplied record |
Essential Medicines List (EML) status was not provided.
Safety Considerations
No SAHPRA package insert warnings, contraindications or drug interaction data were available in the evidence pack. Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Safety signals in the retrieved literature (individual case reports, not systematic data):
- Life-threatening hyperkalaemia and acute kidney dysfunction in a patient taking telmisartan on a low-sodium (potassium-rich) diet (PMID 21373319).
- Possible etoricoxib-induced reversible cerebral vasoconstriction syndrome (PMID 25229174). This is a vascular signal to weigh in any headache or migraine use.
- Selective COX-2 inhibitors are associated with fluid retention and hypertension.
Conclusion and Next Steps
Decision: Hold
Rationale: The migraine prediction is supported only by the model score and a plausible COX-2 mechanism, with no trials or publications for this drug-disease pair. Case-level reports in related headache disorders are interesting, but they are not enough to move forward, and the vascular safety signals need weighing.
To proceed, the following is needed:
- The SAHPRA Professional Information (package insert) warnings and contraindications. This is a blocking gap.
- Detailed mechanism of action data (for example from DrugBank).
- The approved indication text for Reg. No. 49/20.2.8/0399, to establish the baseline use.
- Controlled clinical evidence in migraine, or at least systematic evidence in the related headache disorders.
- A cardiovascular, renal and cerebrovascular risk assessment for the intended population.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.